최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기약학회지 = Yakhak hoeji, v.57 no.1, 2013년, pp.43 - 54
김충섭 (한국과학기술 정보연구원)
Viral hepatitis is the inflammation of liver cells caused by viruses, and still one of the major health-care problems worldwide. A number of viruses to cause hepatitis are type A, B, C, D, E or G. Among these viruses leading to hepatitis, B and C are more troublesome being more prone to chronic illn...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
바이러스성 간질환이란 무엇인가? | 바이러스성 간질환은 바이러스가 인체의 간에 침입하여 여러가지 병적인 증상을 나타내는 전염성이 매우 강한 질병으로, 바이러스의 종류에 따라 A, B, C, D, E, G형으로 분류한다. 전 세계적으로는 바이러스성 만성간질환 환자가 약 5억 명에 이르고, 특히 B와 C형의 만성 간염 환자는 1억5천 명 정도로 이들은 간경변이나 간암으로 발전하여 매년 백만 명이 사망하고 있다. | |
A형 간염백신의 불활성화 백신은 어떻게 제조되는가? | A형 간염백신은 제조방법에 따라 바이러스를 불활성화 한 백신과 virosome 기술을 이용한 합성백신이 있다. 불활성화 백신은 환자로 부터 분리한 바이러스종(HM175, CR326F, GBM, RGSB strain)을 원숭이나 인체의 신장세포나 또는 인체의 폐섬유아 세포(MRC-5; human lung fibriblast cell)에 감염시켜 배양한 후 바이러스만을 분리 정제하여 포르마린으로 불활성화 시켜서 백신보조제(vaccine adjuvant), alum을 첨가하여 제조한다.3) | |
Virosome의 역할은 무엇인가? | Virosome은 바이러스 단백질과 지질을 함유한 바이러스막의 인공 고분자입자로서 백신운반체와 첨가제 두 가지 역할을 한다. 특히 virosome은 목표 면역세포에 특이항체를 전달하거나 DNA/ RNA가 부호화된 특이 면역단백질을 제공하여 세포면역반응과 항체를 동시에 유도하는 인체 면역계 양쪽을 활성화 시키는 새로운 인공백신 제조기술이다. |
HB El-Serag : Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264 (2012).
Karayiannis, P. : Direct Acting Antivirals for the treatment of chronic viral hepatitis. Scientifica Review 1 (2012).
European Pharmacopoeia 5.0, (2005), Hepatitis A Vaccine (inactivated, adsorbed).
Pevion Biotech Ltd., Website: www.pevion.com/images/content/pevion_virosomesheet_vaccines_Oct4.pdf, :Virosomal Vaccine Plaftforms. Oct. 2012.
Christian Moser, Ian C Metcalfe and Jean-Franois Viret : Virosomal adjuvant antigen delivery systems. Expert Reviews Vaccine 2, 189 (2003).
Valrie D'Acremont, Christian Herzog and Blaise Genton : Immunogenicity and safety of a virosomal hepatitis A vaccine ( $Epaxal^{(R)}$ ) in the elderly. J. of Travel Medicine 13, 78 (2006).
Steven G. Reed, Sylvie Bertholet, Rhea N. Coler and Martin Friede : New horizons in adjuvants for vaccine development. Trends in Immunology 30, 23 (2009).
GamaSTAN Website http://www.talecris-pi.info/inserts/gamastans-d.pdf, "Immune globulin (Human)", April. 2012.
박상훈 : A형간염 : 과거와 현재. J. Kor. Med. Assoc. 52, 996 (2009).
정숙향 : A형 간염백신. Hanyang Medical Rewiew 28, 16 (2008).
이응준 : 최근 2년간 발생한 급성 A형간염의 임상특성에 관한 연구. 대한소화기학회지 52, 298 (2008).
Moon, H. W., Cho, J. H., Hur, M., Yun, Y.-M., Choe, W. H., Kwon, S. Y. and Lee, C. H. : Laboratory characteristics of recent hepatitis A in Korea : Ongoing epidemiological shift. World J. Gastroenterol. 16, 1115 (2010).
Lee, H., Cho, H. K., Kim, J. H. and Kim, K. H. : Seroepidemiology of Hepatitis A in Korea : Changes over the Past 30 Years. J. Korean Med. Sci. 26, 791 (2011).
Barakat, A. B., Shoman, A. S., Dina, N. and Alfarouk, O. R. : Antiviral activity and mode of action of Dianthus caryophyllus L. and Lupinus termes L. seed extracts against in vitro herpes simplex and hepatitis A viruses infection. J. Microb. & Antimicrobials 2, 23 (2010).
Dandri, M. and Locarnini, S. : New insight in the pathobiology of hepatitis B virus infection. Gut 61, i6 (2012).
D. Shouval, Hepatitis B vaccines. Journal of Hepatology 39, S70 (2003).
Dynavax Website, http://www.dynavax.com/hepatitis_bv.html.
Marcellin, P., Chang, T. T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., Fry, J. and Brosgart, C. L. : Adefovir Dipivoxil 437 Study Group. : Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 8081 (2003).
Sims, K. A. and Woodland, A. M. : Entecavir a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy 269, 1745 (2006).
Lai, C. L., Gane, E., Liaw, Y. F. and Hsu, C. W. : Pharmacokinetics and dosing recommendation of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin. Pharmacokinet. 45, 11151 (2006).
Lai, C. L., Gane, E., Liaw, Y. F. and Hsu, C. W. : Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Eng. J. Med. 257, 2576 (2007).
Yuen, M. F. and Lai, C. L. : Current and future antiviral agents for chronic hepatitis B. J. Antimicrobial Chemotherapy 51, 481 (2003).
Lee, K., Chang, S. and Su, Y. : Clinical and virologic outcomes after switch to tenoforvir/lamibudine of HIV infected patients with hepatitis B virus (HBV) resitance to lamibudine in an hyperendemic area for HBV infection, 52nd Intersci. Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract H-218 (2012).
Perrillo, R. P. and Marcellin, P. : Effect of newer oral antiviral agents on future therapy of chronic hepetitis B. Antiviral Therapy 15, 13 (2010).
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D. K., Pham, B., Ungar, W. J., Einarson, T. R., Heathcote, E. J. and Krahn, M. : Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and bayesian meta-analyses. Gastroenterology 139, 1218 (2010).
Lee, H. S., Chung, Y. H., Lee, K., Byun, K. S., Paik, S. W., Han, J. Y., Yoo, K., Yoo, H. W., Lee, J. H. and Yoo, B. C. : A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg- positive chronic hepatitis B. Hepatology 43, 982 (2006).
Lau, G. K. and Leung, N. : Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J. Hepatol. 16, 315 (2010).
Yuen, M. F., Han, K. H., Um, S. H., Yoon, S. K., Kim, H. R., Kim, J., Kim, C. R. and Lai, C. L. : Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 51, 767 (2010).
Brunelle, M. N., Lucifora, J., Neyts, J., Holy, V. A., Trepo, C. and Zoulim, F. : In vitro activity of 2,4-diamino-6-[2-(phosphomethoxy) ethoxy]pyrimidine against multidrug resistant hepatitis B virus mutants. Antimicrob Agents Chemotherapy 51, 2240 (2007).
Balzarini, J., Pannecouque, C., Naesens, L., Andrei, G., Snoeck, R., Clercq, E. D. and Hockova, D. : A 6-[2-phosphonomethoxy) alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleotides Nucleic Acids 23, 1321 (2004).
Kim, S. H. : HBV neutralizing human monoclonal antibody (GC1102) for liver transplantation & chronic hepatitis B treatment. 한국생물공학회 학술대회 초록, p. 91 (2010).
Grimm, D., Thimme, R. and Blum, H. E. : HBV life cycle and novel drug target. Hepatol. Int. 5, 644 (2011).
Ryu, D.-K., Ahn, B.-Y. and Ryu, W.-S. : Proximity between the cap and 5' ${\varepsilon}$ stemploop structure is critical for the suppression of pgRNA translation by the hepatitis B viral polymerase.Virology 406, 56 (2010).
Chou, L. : Hepatitis B Drugs i9n Development. TAG 2010 Pipe Line Report, pp. 70-76 (2010).
Seto, W. K., Fung, J., Yuen, M. F. and Lai, C. L. : Future prevention and treatment of chronic hepatitis B infection. J. Clin. Gastroenterol. 46, 725 (2012).
Hofmann, W. P. and Zeuzem, S. A. : New standard of care for the treatment of chronic HCV infection. Nature Reviews Gastroenterology & Hepatology 8, 257 (2011).
Jason Grebely, Gail V. Matthews and Gregory J. Dore : Treatment of acute HCV infection. Nat. Rev. Gastroenterol. and Hepatol. 8, 265 (2011).
Asselah, T. and Marcellin, P. : Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver International 32, 88 (2012).
Owsianka, A. M., Tarr, A. W. and Keck, Z. Y. : Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89, 6536 (2008).
Giang, E., Dorner, M. and Prentoe, J. C. : Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. PNAS 109, 6205 (2012).
Kong, L., Giang, E. and Robbins, J. B. : Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. USA 109, 9499 (2012).
Barnes, E., Folgori, A., Capone, S., Swadling, L. and Aston, S. : Novel adenovirus-based vaccines induce broad and sustained T cell responces to HCV in man. Sci. Transl. Med. 4, 115ra1 (2012).
Greenhill, Hepatitis: HCV vaccine is successful in phase I study in healthy volunteers. Nat. Rev. Gastroenterol Hepatol. 9, 126 (2012).
Harrison, Viral disease: Steps towards an HCV vaccine. Nat. Rev. Drug Discov. 11, 187 (2012).
Sharma SD, Hepatitis C virus: Molecular biology and current therapeutic options. Indian J. Med. Res. 131, 17 (2010).
Leung, D., Abbenante, G. and Fairlie, D. P. : Protease inhibitors: Currenr status and future prospects. J. Med. Chem. 43, 305 (2000).
Hofmann, W. P. and Zeuzem, S. : A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. and Hepatol. 8, 257 (2011).
Proceedings of the 5th Paris Hepatitis Conference. International Conference of the Management of Patients with Viral Hepatitis: Special Edition Hepatitis C. Liver International 32, 1 (2012).
Jana Schuetter : New drugs hit the target. Nature 474, 55 (2011).
Rice : New insights into HCV replication: potential antiviral targets. Topics in Antiviral Med. 19, 117 (2011).
Manja : New Immunomodulators. 1st Global Work Shop on HCV Therapy Advances, 119-10, Oct. 2011, Madrid, Spain.
www.hcvdrug.com. : Hepatitis C New Drug Pipeline; Clayden : Hepatitis C drug development goes from pony ride to rocket launch, TAG 2012 Pipeline Report, pp. 137-184 (2012).
Jean-Michel Pawlotsky : New Antiviral Agents for Hepatitis C, F1000 Biology Reports 2012, 4:5.
Muir, A. J., Shiffman, M. L., Zaman, A. and Yoffe, B. : Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822 (2010).
Guidance for Industry, Chronic Hepatitis C Virus Infection: Developing Directing-Acting Antiviral Agents for treatment, U.S. FDA, Center for Drug Evaluation and Research.
Pham, L. V., Ngo, H. T., Lim, Y. S. and Hwang, S. B. : Hepatitis C virus non-structural 5B protein interacts with cyclin A2 and regulates viral propagation. Journal of Hepatology 57, 960 (2012).
Park, J., Kang, W., Ryu, S.-W., Kim, W.-I., Chang, D.-Y. and Lee, D. H. : Hepatitis C virus infection enhances TNF- ${\alpha}$ induced cell death via suppression of NF- ${\kappa}B$ . Hepatology 56, 831 (2012).
Jeong : CD11b+GDr1+bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology, Accepted manuscript online: 27 APR (2012).
Eskandar Hajiani, Seyed Mohammad Alavi : A review on epidemiology, diagnosis and treatment of hepetitis D virus infection. Jundishapur J. of Microbiology 4, s1 (2011).
V Chandra, S Taneja, M Kalia : Molecular biology and pathogenesis of hepatitis E virus. J. Biosci. 33, 451 (2008).
Feng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, Cheng Zhou : Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. The Lancet 376, 895 (2010).
Shrestha, M. P., Scott, R. Mc., Joshi, D. M., Mammen, M. P., Welsch1, C. and Jesudian, A. : Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356, 895 (2007).
Fellay, G. D. : Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 46, 399 (2009).
Kimer, N., Dahl, E. K., Gluud, L. L. and Krag, A. : Antiviral therapy for prevention of hepatocellular carcinoma. BMJ Open 2 (2012).
Jahan, S., Ashfa, U. A., Qasim, M., Khaliq, S., Saleem and Nadeem, M. J. : Hepatitis C virus to hepatocellular carcinoma. Infectious Agents and Cancer 7:2 (2012).
Tran, G. : The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma. BioscienceHorizones 1, 167 (2008).
Welsch, C., Jesudian, A. and Zeuzem, S. : New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61, i36 (2012).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.